Precision oncology is entering a new era—one defined by earlier detection, personalised treatment, and the growing potential for long-term remission or cure. In this paper, we explore how advances such as liquid biopsy, minimal residual disease testing, and next-generation therapies are accelerating the shift from treatment to prevention. The analysis highlights why oncology remains one of the most innovative and resilient segments within healthcare.
Every year on 4 February, World Cancer Day brings global attention to the progress made—and the challenges that remain—in the fight against cancer. While the disease continues to affect millions of people worldwide, recent advances in oncology are reshaping expectations. Scientific innovation is enabling earlier detection, more precise treatments, and, increasingly, the possibility of long-term remission or cure in selected patients.
Breakthroughs in molecular diagnostics, targeted therapies, immunotherapies, and cell-based treatments are transforming cancer care from a one-size-fits-all approach into a more personalised and preventive discipline. This progress offers renewed hope to patients, while also redefining the future of healthcare systems and investment in medical innovation.
Candriam’s Healthcare investment team has published an in-depth paper exploring how precision oncology is moving beyond late-stage treatment toward earlier intervention, metastatic prevention, and curative intent.
Precision oncology is accelerating through a combination of complementary innovations, such as:
Together, these developments are reshaping cancer care while redefining how healthcare systems allocate resources and how innovation creates long-term value.
Beyond its medical impact, oncology stands out as one of the most dynamic and resilient segments within healthcare.
Strong demographic trends, high unmet medical needs and sustained R&D investment continue to fuel innovation across the oncology value chain — from diagnostics to therapies and enabling technologies.
Candriam’s Healthcare investment team has published an in-depth research paper exploring the most recent and promising breakthroughs, and what these transformations mean for patients, clinicians and investors alike.
At Candriam, we view oncology as a long-term structural growth theme driven by strong demographic trends, unmet medical needs, and sustained innovation. Our oncology strategy focuses on :
By aligning medical innovation with rigorous investment analysis, Candriam aims to contribute to the future of cancer care while creating sustainable value for investors.
Oncology: A key investment opportunity
A combination of compelling fundamentals, powerful growth drivers and high-pace innovation makes oncology one of the fastest developing fields. Read why you should consider investing in the oncology market today.
Get information faster with a single click